Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study

Anticancer Research

Volumn 21, Issue 1 B, 2001, Pages 789-795

  Cardoso, F ^a   Ferreira Filho, A F ^a   Crown, J ^a   Dolci, S ^a   Paesmans, M ^a   Riva, A ^a   Di Leo, A ^a   Piccart, M J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Docetaxel; Doxorubicin; Drug sequencing

Indexed keywords

DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CONJUNCTIVITIS; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; INCIDENCE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0035062733     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Malignant tumours of the breast
2. Future perspectives of docetaxel (Taxotere) in front-line therapy
3. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
4. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer
5. Sequential versus alternating regimens in the treatment of advanced breast cancer. Argentine Breast Cancer Cooperative Group
6. Docetaxel (Taxotere) plus doxorrubicin-based combinations: The evidence of activity in breast cancer
7. Feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer
8. Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics
9. Taxoids in combination with anthracyclines and other agents: Pharmacokinetics considerations
10. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies
11. Phase II study of sequential docetaxel and doxorubicin as primary chemotherapy for large operable breast cancer
12. Cytotoxic agents with activity in breast cancer. Patients previously exposed to anthracyclines: Current status and future prospects
13. Phase 2 trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
14. Docetaxel as a single-agent therapy in metastatic breast cancer: Clinical efficacy
15. Prospects with docetaxel in the treatment of patients with breast cancer
16. Adjuvant chemotherapy of sequential docetaxel and adriamycin in patients with completely resected breast cancer: Preliminary report
17. Sequential administration of docetaxel followed by AC in first line metastatic breast cancer patients: Final results
18. Antracycline as second line chemotherapy for metastatic breast cancer, in patients previously treated with docetaxel
19. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2
20. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trail of the hoosier oncology group
21. A phase II randomized study of doxorubicin (A) alterned to docetaxel (T) (ALT) vs sequential administration of 4 cy of t followed by 4 cy of a (seq) as 1st line ct in mbc pts
22. Docetaxel in combination chemotherapy for metastatic breast cancer
23. Phase II study of taxotere, doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer
24. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer